Those in the rare disease community are our heroes. See how we’re empowered to put them first.
We are creative collaborators motivated by the real-world impact of our treatments.
Dier joined Acelyrin from Ultragenyx Inc., where she most recently served as executive vice president and chief financial officer.
Nov 10, 2022 | sfvbj.comUltragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that Mardi Dier, Chief Financial Officer (CFO) and Executive Vice President, is leaving the company, effective November 15, 2022, to assume the dual role of CFO and Chief Business Development Officer at privately held ACELYRIN, INC.
Nov 9, 2022 | ultragenyx.comUltragenyx Appoints Amrit Ray, M.D., M.B.A. to Board of Directors Amrit Ray, M.D., M.B.A. NOVATO, Calif., April 22, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced the appointment of Amrit Ray, M.D., M.B.A. to the company’s Board of Directors.
Jan 1, 2022 | ultragenyx.comRegeneron is taking care of development and distribution in the U.S. and is collaborating with Ultragenyx for activities outside the country.
Jan 1, 2022 | biospace.comRegeneron is responsible for developing and distributing Evkeeza in the U.S. and is collaborating with Ultragenyx ( RARE ) to develop and sell Evkeeza outside the U.S.
Jan 1, 2022 | seekingalpha.com“Ultragenyx has successfully launched Crysvita, meaningfully improving the lives of thousands of pediatric and adult patients with two rare diseases.
Jan 1, 2022 | omerscapitalmarkets.comUltragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare diseases, and GeneTx Biotherapeutics LLC, today announced a partnership to develop GeneTx’s GTX-102, an antisense oligonucleotide (ASO) for the treatment of Angelman syndrome, a serious, debilitating, rare neurogenetic disorder that affects approximately 1 in 15,000 people worldwide.
Jan 1, 2020 | genetxbio.comIn August 2019, Ultragenyx and GeneTx announced a partnership to develop GTX-102 with Ultragenyx receiving an exclusive option to acquire GeneTx.
Jan 1, 2020 | genetxbio.comIn August 2019, GeneTx and Ultragenyx announced a partnership to develop GTX-102, with Ultragenyx receiving an exclusive option to acquire GeneTx.
Jan 1, 2020 | genetxbio.comUltragenyx Pharmaceutical Inc. and partner Kyowa Hakko Kirin Co. Ltd. (KHK) have won FDA approval for Crysvita (burosumab), making it the first U.S.-approved treatment for X-linked hypophosphatemia (XLH), a rare, inherited form of rickets.
Jan 1, 2018 | bioworld.com